Abstract The standard treatments of glioblastoma include surgery, postoperative radiotherapy and concurrent and adjuvant temozolomide-based chemotherapy. Radiotherapy is directly related to the overall survival rate. Nevertheless, the standard delineation of target volume during radiotherapy remains controversial. In this article, different standpoints upon the range of delineation of tumor volume were analyzed and the recurrence pattern of glioblastoma after radiotherapy was summarized. Besides, the technical causes of the failure to accurately delineate the tumor outline were identified. It is of significance to deliver individualized delineation of target volume by referring to the clinical and pathological characteristics of each patient. Finally, the application prospect of radiotherapy in the treatment of glioblastoma was discussed in this article, aiming to enhance the accuracy of target volume delineation during radiotherapy and maximize the clinical benefits to the patients.
Lin Lin,Zhou Juying. The progress on the delineation of target volume in postoperative intensity-modulated radiotherapy for glioblastoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 317-320.
Lin Lin,Zhou Juying. The progress on the delineation of target volume in postoperative intensity-modulated radiotherapy for glioblastoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 317-320.
[1] Lo SS,Sahgal A,Slotman BJ,et al. What is the mostappropriateclinical targetvolumeforglioblastoma?[J].CNS Oncol,2013,2(5):419-425.DOI:10.2217/cns.13.38. [2] Niyazi M,Brada M,Chalmers AJ,et al. ESTRO-ACROP guideline “target delineation of glioblastomas”[J].Radiother Oncol,2016,118(1):35-42.DOI:10.1016/j.radonc.2015.12.003. [3] McDonald MW,Shu HK,Curran WJ Jr,et al. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma[J].Int J Radiat Oncol Biol Phys,2011,79(1):130-136.DOI:10.1016/j.ijrobp.2009.10.048. [4] Buglione M,Pedretti S,Poliani PL,et al. Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy:Could amargin reduction be proposed?[J].J Neurooncol,2016,128(2):303-312.DOI:10.1007/s11060-016-2112-2. [5] Jansen EP,Dewit LG,van Herk M,et al. Target volumes in radiotherapy for high-grade malignant glioma of the brain[J].Radiother Oncol,2000,56(2):151-156. [6] Choi SH,Kim JW,Chang JS,et al. Impact of including peritumoral edema in radiotherapy target volume on patterns of failure in glioblastoma following temozolomide-based chemoradiotherapy[J].Sci Rep,2017,7:42148.DOI:10.1038/srep42148. [7] Chang EL,Akyurek S,Avalos T,et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumesfor glioblastoma[J].Int J Radiat Oncol Biol Phys,2007,68(1):144-150. [8] Minniti G,Amelio D,Amichetti M,et al. Patterns of failure and comparison of different target volume delineations in patients withglioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide[J].Radiother Oncol,2010,97(3):377-381.DOI:10.1016/j.radonc.2010.08.020. [9] Gebhardt BJ,Dobelbower MC,Ennis WH,et al. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrenttemozolomide[J].Radiat Oncol,2014,9:130.DOI:10.1186/1748-717X-9-130. [10] Berberat J,McNamara J,Remonda L,et al. Diffusion tensor imaging for target volume definition in glioblastoma multiforme[J].Strahlenther Onkol,2014,190(10):939-943.DOI:10.1007/s00066-014-0676-3. [11] Farace P,Giri MG,Meliadò G,et al. Clinical target volume delineation in glioblastomas:pre-operative versus post-operative/pre-radiotherapy MRI[J].Br J Radiol,2011,84(999):271-278.DOI:10.1259/bjr/10315979. [12] Lopez CJ,Nagornaya N,Parra NA,et al. Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of GlioblastomaMultiforme[J].Int J Radiat Oncol Biol Phys,2017,97(3):586-595.DOI:10.1016/j.ijrobp.2016.11.011. [13] Dhermain F.Radiotherapy of high-grade gliomas:current standards and new concepts,innovations in imaging and radiotherapy,and new therapeutic approaches[J].Chin J Cancer,2014,33(1):16-24.DOI:10.5732/cjc.013.10217. [14] Bette S,Barz M,Wiestler B,et al. Prognostic value of tumor volume in glioblastoma patients:Size also matters for patients with in complete resection[J].Ann Surg Oncol,2017,20.DOI:10.1245/s10434-017-6253-0. [15] Zhao F,Li M,Kong L,et al. Delineation of radiation therapy target volumes for patients with postoperative glioblastoma:areview[J].Onco Targets Ther,2016,9:3197-3204.DOI:10.2147/OTT.S104241. [16] Mistry AM,Hale AT,Chambless LB,et al. Influence of glioblastoma contact with the lateral ventricle on survival:a meta-analysis[J].J Neurooncol,2017,131(1):125-133.DOI:10.1007/s11060-016-2278-7. [17] Liang HT,Chen WY,Lai SF,et al. The extent of edema and tumor synchronous invasion into the subventricular zone and corpuscallosum classify outcomes and radiotherapy strategies of glioblastomas[J].Radiother Oncol,2017,125(2):248-257.DOI:10.1016/j.radonc.2017.09.024. [18] Dunn J,Baborie A,Alam F,et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy[J].Br J Cancer,2009,101(1):124-131.DOI:10.1038/sj.bjc.6605127. [19] Jue TR,Nozue K,Lester AJ,et al. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylatedglioblastoma[J].J Transl Med,2017,15(1):61.DOI:10.1186/s12967-017-1164-1. [20] Pitter KL,Tamagno I,Alikhanyan K,et al. Corticosteroids compromise survival in glioblastoma[J].Brain,2016,139(Pt 5):1458-1471.DOI:10.1093/brain/aww046. [21] Wang XF,Lin GS,Lin ZX,et al. Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosedglioblastoma:an immunohistochemical study[J].Int J Clin Exp Pathol,2014,7(9):6133-6140. [22] Takano S,Kimu H,Tsuda K,et al. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment ofrecurrent glioblastoma treated by bevacizumab[J].Acta Neurochir Suppl,2013,118(1):185-189.DOI:10.1007/978-3-7091-1434-6_34. [23] Darmon I,Morisse MC,Coutte A,et al. Temozolomide and bevacizumab induction before chemoradiotherapy in patients with bulky glioblastoma and/or with severe neurological impairment[J].J Cancer,2017,8(8):1417-1424.DOI:10.7150/jca.18339.
2019, Vol. 28 
